EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSEMKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that its innovative new FDA-cleared product, the intelli-Case™, was featured in news segments on the San Francisco Bay Area’s ABC affiliate KGO-TV.
In the segments, which aired on the 6 p.m. and 11 p.m. news on August 21, ABC news anchor Eric Thomas explained that improperly cleaned and disinfected contact lenses can expose the eye to bacteria and fungi, and cause serious infections. In fact, a new CDC survey shows that nearly one million Americans go to the doctor every year because of eye infections, mainly caused by unsterilized contact lenses. Some of those infections can lead to blindness.
“The best way to completely sterilize contact lenses is to disinfect them with hydrogen peroxide solution,” Thomas said. The problem is that if the hydrogen peroxide is not used properly, it can burn the eye. As such, its use has fallen out of favor with many consumers.
But as the segment describes, NovaBay Pharmaceuticals has developed a product that safely harnesses the power of hydrogen peroxide. The company’s new intelli-Case device ensures that lenses are fully disinfected and safe to put in the eye.
How? As Thomas explained, “A computer chip inside the intelli-Case analyzes the chemical balance of the hydrogen peroxide to make sure it's been neutralized by the end of the cleaning process. A light on the case switches from yellow to green when it's safe to remove the lenses. If there's a problem and you use the wrong solution or the catalyst has gone bad, for any reason, the red light will blink.”
The complete segment is available at http://abc7news.com/health/contact-lens-disinfecting-goes-digital/951658/.
NovaBay plans to begin test marketing the intelli-Case in the San Francisco Bay Area later this year with a staged product rollout in 2016.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, cleared by the U.S. FDA as 510(k) medical device; the NEUTROX™ Family of Products includes AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, and CELLERX™ for the cosmetic surgery and aesthetic dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™, which is in development as a new drug in urology and dermatology. NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North Africa and Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (Ukraine).
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the future commercialization and market acceptance of intelli-Case. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay's progress: